3 ms·
And congrats to Ginko on recent $120M deal with Cronos Group. Engineering yeast strains that can produce full-spectrum of cannabinoids via fermentation at facto
by ArtWomb 8y ago
And congrats to Ginko on recent $120M deal with Cronos Group. Engineering yeast strains that can produce full-spectrum of cannabinoids via fermentation at factory scale. Really exciting!
https://thecronosgroup.com/investor-relations/ https://thecronosgroup.com/investor-relations/
- jamestimmins 8y agoMind explaining what this means and why it's exciting?
- ArtWomb 8y agoMaybe some Ginko peeps can chime in ;) But I'm very impressed with the scale. $100M is ballpark scale of all cannabis US research funding per annum. And most trials investigate CBD, THC. There are hundreds of other cannabinoid compounds worth investigating. Providing high quality samples to researchers will result in discoveries. A single cannabis breakthrough treatment changes the entire game. Plus, expertise for Ginko with synthesizing cannabinoids conceivably translates to opiods and myriad other medicinal plants compounds.